$0.49 EPS Expected for Ormat Technologies, Inc. (ORA); Bio Rad Laboratories (BIO) Sentiment Is 1.03

July 12, 2018 - By Daniel Cummings

Ormat Technologies, Inc. (NYSE:ORA) Logo

Bio Rad Laboratories Inc (BIO) investors sentiment decreased to 1.03 in Q1 2018. It’s down -0.10, from 1.13 in 2017Q4. The ratio fall, as 123 investment professionals increased or opened new stock positions, while 119 decreased and sold equity positions in Bio Rad Laboratories Inc. The investment professionals in our database now hold: 18.53 million shares, down from 18.57 million shares in 2017Q4. Also, the number of investment professionals holding Bio Rad Laboratories Inc in top ten stock positions decreased from 4 to 3 for a decrease of 1. Sold All: 18 Reduced: 101 Increased: 81 New Position: 42.

Analysts expect Ormat Technologies, Inc. (NYSE:ORA) to report $0.49 EPS on August, 2.They anticipate $0.09 EPS change or 15.52% from last quarter’s $0.58 EPS. ORA’s profit would be $24.80 million giving it 26.55 P/E if the $0.49 EPS is correct. After having $0.48 EPS previously, Ormat Technologies, Inc.’s analysts see 2.08% EPS growth. The stock increased 1.17% or $0.6 during the last trading session, reaching $52.04. About 173,440 shares traded. Ormat Technologies, Inc. (NYSE:ORA) has declined 10.26% since July 12, 2017 and is downtrending. It has underperformed by 22.83% the S&P500. Some Historical ORA News: 23/04/2018 – News On U.S. Geothermal Inc. (HTM) Now Under ORA; 16/05/2018 – Ormat: Company Is Further Delaying the Filing of the Quarterly Report on Form 10-Q for 1Q 2018 With SE; 16/05/2018 – Ormat Previously Reported It Identified a Material Weakness in Its Internal Control Over Financial Reporting Related to Accounting for Income Taxes; 03/05/2018 – Ormat Technologies Signs $125 Million Non-Recourse Finance Agreement with OPIC for the Platanares Geothermal Power Plant in Hon; 28/05/2018 – ORMAT TECHNOLOGIES INC SAYS COMPANY CANNOT ASSESS AT THIS STAGE EXTENT OF DAMAGE TO FUTURE FUNCTIONALITY OF HAWAIIAN WELLS; 16/05/2018 – Ormat Announces That It Will Restate Its Second, Third and Fourth Quarter and Full-Year 2017 Financial Statements; Announces Delay in Filing Its First Quarter 2018 Financial Statements; 08/05/2018 – ORMAT: SARULLA GEOTHERMAL POWER PLANT EXPANDS TO 330 MW; 16/05/2018 – Bragar Eagel & Squire, P.C. is Investigating Ormat Technologies, Inc. (ORA) on Behalf of Stockholders and Encourages Investors; 11/05/2018 – ORMAT TECHNOLOGIES – NETTED SOME DEFERRED INCOME TAX ASSETS & LIABILITIES ACROSS DIFFERENT TAX JURISDICTIONS NOT PERMITTED PURSUANT TO U.S. GAAP; 16/05/2018 – Ormat: Restatement Decision Based on Its Conclusion That There Were Errors in the Income Tax Provision

Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on August, 2. They expect $1.35 earnings per share, up 132.76% or $0.77 from last year’s $0.58 per share. BIO’s profit will be $39.95 million for 55.98 P/E if the $1.35 EPS becomes a reality. After $1.17 actual earnings per share reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 15.38% EPS growth.

The stock increased 0.93% or $2.8 during the last trading session, reaching $302.27. About 83,800 shares traded. Bio-Rad Laboratories, Inc. (BIO) has risen 30.04% since July 12, 2017 and is uptrending. It has outperformed by 17.47% the S&P500. Some Historical BIO News: 08/05/2018 – BIO-RAD SEES FY REV. CHANGE EX-FX +3.5% TO +4%; 16/03/2018 – BIO RAD LABORATORIES – KPMG NOTIFIED SENIOR MANAGEMENT IT REQUIRED MORE TIME TO COMPLETE AUDIT OF 2017 FINANCIAL STATEMENTS – SEC FILING; 16/03/2018 – Bio-Rad Labs: Internal Control Over Financial Reporting Not Effective as of Dec. 31; 16/03/2018 – Bio-Rad Laboratories Unable to File 2017 Form 10-K by March 16 Extended Deadline; 16/03/2018 – BIO RAD LABORATORIES SAYS IDENTIFIED CERTAIN INTERNAL CONTROL DEFICIENCIES ARISING FROM APRIL 2017 ERP SYSTEM & BUSINESS STRUCTURE CONVERSION; 08/05/2018 – Bio-Rad Laboratories 1Q Adj EPS $1.17; 08/05/2018 – Bio-Rad Laboratories 1Q EPS $21.77; 18/05/2018 – Research Report Identifies Bio-Rad Laboratories, Bright Horizons Family Solutions, Corbus Pharmaceuticals, PennyMac Financial S; 07/03/2018 NYSE HALT BIO-RAD LABS B BlOb.N ADDITIONAL INFORMATION LAST $244.70000; 16/03/2018 – Bio-Rad Labs Delay Prompted by Conversion to New ERP System, Business Structure for European Operations

Since January 1, 0001, it had 0 buys, and 1 sale for $106,197 activity.

Tikvah Management Llc holds 11.48% of its portfolio in Bio-Rad Laboratories, Inc. for 149,407 shares. Sector Gamma As owns 94,240 shares or 4.25% of their US portfolio. Moreover, Beaconlight Capital Llc has 3.52% invested in the company for 37,490 shares. The Georgia-based Atlanta Capital Management Co L L C has invested 1.9% in the stock. Hitchwood Capital Management Lp, a New York-based fund reported 150,000 shares.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company has market cap of $8.95 billion. The firm operates through two divisions, Life Science and Clinical Diagnostics. It has a 11.86 P/E ratio. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

More news for Bio-Rad Laboratories, Inc. (NYSE:BIO) were recently published by: Benzinga.com, which released: “Benzinga’s Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares” on July 11, 2018. Gurufocus.com‘s article titled: “John Rogers’ Ariel Investments June Commentary” and published on July 09, 2018 is yet another important article.

Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.26, from 0.96 in 2017Q4. It dived, as 21 investors sold Ormat Technologies, Inc. shares while 66 reduced holdings. 20 funds opened positions while 41 raised stakes. 20.95 million shares or 1.67% less from 21.31 million shares in 2017Q4 were reported. Fdx Advsr stated it has 8,278 shares. Cubist Systematic Strategies reported 0.01% in Ormat Technologies, Inc. (NYSE:ORA). 2,614 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Personal Capital Advisors Corporation stated it has 0.08% of its portfolio in Ormat Technologies, Inc. (NYSE:ORA). Kbc Grp Nv holds 72,362 shares or 0.04% of its portfolio. Panagora Asset Mgmt Incorporated accumulated 9,046 shares. Dupont Cap Management holds 0.04% or 32,038 shares. Somerville Kurt F owns 0.18% invested in Ormat Technologies, Inc. (NYSE:ORA) for 14,135 shares. Atlantic Group Llc holds 1,100 shares. Blackrock holds 2.47M shares. Jane Street Group Inc Ltd Liability holds 0.01% of its portfolio in Ormat Technologies, Inc. (NYSE:ORA) for 37,890 shares. United Kingdom-based Guinness Asset Ltd has invested 0.08% in Ormat Technologies, Inc. (NYSE:ORA). Deutsche Bank Ag owns 109,546 shares or 0% of their US portfolio. Vanguard Grp stated it has 3.25 million shares or 0.01% of all its holdings. 220,496 are held by Schwab Charles Inv Incorporated.

Ormat Technologies, Inc. engages in geothermal and recovered energy power business worldwide. The company has market cap of $2.63 billion. The firm operates in two divisions, Electricity and Product. It has a 15.9 P/E ratio. The Electricity segment develops, builds, owns, and operates geothermal and recovered energy power plants; and sells electricity.

More notable recent Ormat Technologies, Inc. (NYSE:ORA) news were published by: Globenewswire.com which released: “CLASS ACTION UPDATE for GLCNF, GLNCY and ORA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on …” on July 12, 2018, also Globenewswire.com with their article: “UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SYMC …” published on July 12, 2018, Globenewswire.com published: “SHAREHOLDER ALERT – PRTA SYMC MFGP ANW ORA PCG TAL FLKS: The Law Offices of Vincent Wong Reminds …” on July 11, 2018. More interesting news about Ormat Technologies, Inc. (NYSE:ORA) were released by: Globenewswire.com and their article: “CLASS ACTION UPDATE for ORA and PCG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of …” published on July 10, 2018 as well as Globenewswire.com‘s news article titled: “Ormat Technologies, Inc. to Host Conference Call Announcing Second Quarter 2018 Financial Results” with publication date: July 10, 2018.

Among 7 analysts covering Ormat Technologies (NYSE:ORA), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Ormat Technologies had 11 analyst reports since January 24, 2018 according to SRatingsIntel. The stock of Ormat Technologies, Inc. (NYSE:ORA) earned “Buy” rating by Roth Capital on Friday, March 2. The stock has “Buy” rating by Cowen & Co on Thursday, March 1. The stock of Ormat Technologies, Inc. (NYSE:ORA) earned “Hold” rating by UBS on Friday, March 16. J.P. Morgan downgraded Ormat Technologies, Inc. (NYSE:ORA) on Monday, May 14 to “Hold” rating. The stock has “Buy” rating by Cowen & Co on Wednesday, January 24. The rating was downgraded by Oppenheimer on Friday, April 6 to “Perform”. On Thursday, January 25 the stock rating was maintained by Roth Capital with “Buy”. JP Morgan maintained Ormat Technologies, Inc. (NYSE:ORA) rating on Thursday, January 25. JP Morgan has “Overweight” rating and $75 target. Guggenheim downgraded the stock to “Neutral” rating in Wednesday, June 13 report. As per Friday, March 16, the company rating was maintained by JP Morgan.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts